With U.S. Biotech companies currently on track for a 75% reduction in going public this year compared to 2021, Intensity remains committed to waiting until market conditions improve while maintaining an active S-1 on file with the SEC.
To weather the storm, a private "cross-over to IPO" financing round has been announced, with details of this round and how it hopes to set the table for a future IPO to be discussed during this interview, which is open to accredited investors and the general public who register here.
As evidenced by multiple Abstracts presented at the recent ASCO conference, the medical community remains confident in the future of Intensity. Under the leadership of CEO Lew Bender, the company has maintained focus and simultaneously expanded the value of Intensity's science by treating additional types of cancers. In July 2022, Intensity Therapeutics, The Ottawa Hospital, and The Ontario Institute for Cancer Research reported INT230-6 demonstrates Tumor Necrosis and Immune Activation in Early Stage Breast Cancers.
With continued progress in ongoing trials plus an improvement in the markets, Intensity will be in a position to complete its Phase 3 trials, which will pave the way for a possible acquisition by Big Pharma. Intensity has already worked with several large potential acquirers, largely due to clinical collaborations with Bristol Myers Squibb and Merck.
About their Lead Product: INT230-6
INT230-6, Intensity’s lead proprietary investigational product candidate, is designed for direct intratumoral injection. INT230-6 was discovered using Intensity’s proprietary DfuseRx℠ technology platform. The drug is composed of two proven, potent anti-cancer agents, cisplatin and vinblastine, and a penetration enhancer molecule that helps disperse the drugs throughout tumors for diffusion into cancer cells. In addition to local disease control, direct killing of the tumor by INT230-6 releases a bolus of neoantigens specific to the patient’s malignancy, leading to engagement of the immune system and systemic anti-tumor effects. Importantly, these effects are mediated without the immunosuppression of concomitant systemic chemotherapy.
INT230-6 is currently being evaluated in several phase 2 cohorts (NCT03058289) in patients with various advanced solid tumors as part of Study IT-01. In 2019, the Company signed a clinical collaboration agreement with Merck Sharpe & Dohme (Merck) to evaluate the combination of INT230-6 and KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 (programmed death receptor-1) therapy, in patients with advanced pancreatic, colon, squamous cell and bile duct malignancies. In 2020, the Company executed a clinical collaboration agreement with Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Bristol-Myers Squibb’s anti-CTLA-4 antibody, Yervoy® (ipilimumab), in patients with advanced liver, breast and sarcoma cancers. In 2021, the Company executed agreements with the Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase 2 study in women with early stage breast cancer (the INVINCIBLE study) (NCT04781725).
Please join Jim Vaughan and Lew Bender for the live interview on Tuesday, August 16 at 4 pm Central. We welcome and encourage your questions or comments in advance. Please register here.
For more information, please visit www.intensitytherapeutics.com and follow the Company on Twitter @IntensityInc.
VCapital is a Chicago-based venture capital firm focused on early-stage companies. Their strategy is to invest in companies that offer the ability for exceptional, profitable growth. Their investments span medical device, biotechnology, technology, telecommunications and more.